Overview

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2021-03-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Etanercept
Ixekizumab